FDA clears Janux's new drug application for prostrate cancer treatment candidate JANX007
seekingalpha.com
finance
2022-05-31 13:20:42

Waldemarus/iStock via Getty Images 
 Janux Therapeutics (NASDAQ:JANX) on Tuesday said the U.S. Food and Drug Administration had cleared the company's new drug application for its lead product candidate JANX007 for the treatment of prostrate cancer.
JANX007 is the company's lead novel T cell engager therapeutic from its TRACTr platform. The new drug application clearance was specifically for treating metastatic castration-resistant prostate cancer.
Janux said it plans to start an early-stage clinical trial for JANX007 in H2 2022.
